MCID: HYP542
MIFTS: 50

Hypersensitivity Syndrome, Carbamazepine-Induced malady

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Hypersensitivity Syndrome, Carbamazepine-Induced:

Name: Hypersensitivity Syndrome, Carbamazepine-Induced 52 35
Stevens-Johnson Syndrome 52 35 11 48 54 70 50 39 13 68
Toxic Epidermal Necrolysis 52 48 54 70 50 68
Erythema Multiforme Major 48 68
Toxic Epidermolysis 48 54
Sjs-Ten 48 54
Sjs 48 70
 
Severe Cutaneous Adverse Reaction, Susceptibility to Toxic Epidermal Necrolysis, Susceptibility to, Included 52
Hypersensitivity Syndrome, Carbamazepine-Induced, Susceptibility to 12
Dermatostomatitis, Stevens Johnson Type 54
Dermatostomatitis Stevens Johnson Type 70
Schwartz-Jampel Syndrome 68
Ten 70

Characteristics:

Orphanet epidemiological data:

54
stevens-johnson syndrome:
Inheritance: Not applicable; Age of onset: All ages
toxic epidermal necrolysis:
Inheritance: Not applicable; Age of onset: All ages

Classifications:

Orphanet: 54 
Rare skin diseases


External Ids:

OMIM52 608579
Disease Ontology11 DOID:0050426
ICD1030 L51.1, L51.2
ICD9CM32 695.13, 695.15
MeSH39 D013262
ICD10 via Orphanet31 L51.1, L51.2
MESH via Orphanet40 D013262, D004816
UMLS via Orphanet69 C0038325, C0014518
UMLS68 C0014518, C0038325, C1274933 C3658301, C3658302, more

Summaries for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section
NIH Rare Diseases:48 Stevens-Johnson Syndrome (SJS), also called erythema multiforme major, is a limited form of toxic epidermal necrolysis. This disorder affects the skin, mucous membranes and eyes. Stevens-Johnson syndrome occurs twice as often in men as women, and most cases appear in children and young adults under 30, although it can develop in people at any age. Having a gene called HLA-B 1502, increases risk of having Stevens-Johnson syndrome. It is an emergency medical condition that usually requires hospitalization. Treatment focuses on eliminating the underlying cause, controlling symptoms and minimizing complications and includes pain medication to reduce discomfort, medication to relieve itching (antihistamines), antibiotics to control infection, when needed and medication to reduce skin inflammation (topical steroids). Last updated: 7/8/2015

MalaCards based summary: Hypersensitivity Syndrome, Carbamazepine-Induced, also known as stevens-johnson syndrome, is related to psoriasis and stevens-johnson syndrome/toxic epidermal necrolysis, and has symptoms including hypermelanotic macule, weight loss and nausea and vomiting. An important gene associated with Hypersensitivity Syndrome, Carbamazepine-Induced is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways are IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types and Downstream signaling in naive CD8+ T cells. Affiliated tissues include skin, eye and neutrophil, and related mouse phenotype integument.

UniProtKB/Swiss-Prot:70 Stevens-Johnson syndrome: A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

Description from OMIM:52 608579

Related Diseases for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Diseases related to Hypersensitivity Syndrome, Carbamazepine-Induced via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 137)
idRelated DiseaseScoreTop Affiliating Genes
1psoriasis30.2CD4, CD8A
2stevens-johnson syndrome/toxic epidermal necrolysis12.8
3schwartz-jampel syndrome, type 111.8
4ritter's disease11.5
5sjogren's syndrome11.3
6branch retinal artery occlusion10.7HLA-A, HLA-B
7progressive locomotor ataxia10.7HLA-A, HLA-B
8gonococcal iridocyclitis10.7HLA-A, HLA-B
9trigeminal nerve disease10.6FASLG, GZMB
10pediatric systemic lupus erythematosus10.6FAS, FASLG
11erythema multiforme10.5
12mitochondrial encephalomyopathy10.5HLA-A, HLA-B
13granulomatous gastritis10.5FAS, FASLG, GZMB
14steroid dehydrogenase deficiency dental anomalies10.5FAS, FASLG, GZMB
15antigen-peptide-transporter 2 deficiency10.5HLA-A, HLA-B
16arachnoiditis10.4CD8A, HLA-A, HLA-B
17dentinogenesis imperfecta10.4HLA-A, HLA-B, TLR3
18bulbospinal polio10.4CD8A, TLR3
19burns10.4
20clivus chordoma10.4CD4, GZMB
21foster-kennedy syndrome10.4EPHX1, HLA-A, HLA-B
22lupus erythematosus10.4
23acute generalized exanthematous pustulosis10.4
24hypercementosis10.4HLA-A, HLA-B
25hypodermyiasis10.4CD8A, FASLG, GZMB
26ocular hypertension10.3CD4, CD8A
27testicular malignant germ cell cancer10.3FASLG, GZMB
28arteriovenous malformation10.3CD4, CD8A
29actinobacillosis10.3CD4, CD8A
30meckel's diverticulitis10.3CD4, CD8A
31siderosis10.3CD4, FAS, HLA-A
32scrotum squamous cell carcinoma10.3CD4, CD8A
33folliculitis10.3CD4, CD8A
34cd3gamma deficiency10.3CD4, CD8A
35cutaneous lupus erythematosus10.3
36vaccinia10.2CD4, CD8A
37esophagus carcinoma in situ10.2CD4, CD8A
38keratoconjunctivitis10.2CD4, CD8A
39intestinal disaccharidase deficiency10.2CD4, CD8A
40cd3zeta deficiency10.2CD4, CD8A, HLA-A
41penis basal cell carcinoma10.2CD4, CD8A
42chronic eosinophilic pneumonia10.2CD4, CD8A, HSPG2
43partial third-nerve palsy10.2CD4, CD8A, HSPG2
44chediak-higashi syndrome10.2CD4, CD8A, FASLG
45hyperostosis frontalis interna10.1CD4, CD8A, HSPG2
46early congenital syphilis10.1CD4, CD8A, HSPG2
47lacrimal system cancer10.1CD4, CD8A, FAS
48systemic lupus erythematosus10.1
49dermatitis10.1
50eosinophilia10.1

Graphical network of the top 20 diseases related to Hypersensitivity Syndrome, Carbamazepine-Induced:



Diseases related to hypersensitivity syndrome, carbamazepine-induced

Symptoms & Phenotypes for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section


Clinical features from OMIM:

608579

Human phenotypes related to Hypersensitivity Syndrome, Carbamazepine-Induced:

 64 54 (show all 49)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypermelanotic macule64 hallmark (90%) HP:0001034
2 weight loss64 54 hallmark (90%) Very frequent (99-80%) HP:0001824
3 nausea and vomiting64 54 hallmark (90%) Very frequent (99-80%) HP:0002017
4 malabsorption64 hallmark (90%) HP:0002024
5 abnormality of temperature regulation64 hallmark (90%) HP:0004370
6 abnormal blistering of the skin64 54 hallmark (90%) Very frequent (99-80%) HP:0008066
7 acantholysis64 54 hallmark (90%) Very frequent (99-80%) HP:0100792
8 abnormality of neutrophils64 54 typical (50%) Frequent (79-30%) HP:0001874
9 excessive salivation64 54 typical (50%) Frequent (79-30%) HP:0003781
10 feeding difficulties in infancy64 typical (50%) HP:0008872
11 renal insufficiency64 54 occasional (7.5%) Occasional (29-5%) HP:0000083
12 abnormality of the eyelid64 occasional (7.5%) HP:0000492
13 visual impairment64 54 occasional (7.5%) Occasional (29-5%) HP:0000505
14 photophobia64 54 occasional (7.5%) Occasional (29-5%) HP:0000613
15 abnormality of the urethra64 54 occasional (7.5%) Occasional (29-5%) HP:0000795
16 abnormality of the myocardium64 54 occasional (7.5%) Occasional (29-5%) HP:0001637
17 sudden cardiac death64 54 occasional (7.5%) Occasional (29-5%) HP:0001645
18 coronary artery disease64 occasional (7.5%) HP:0001677
19 pancreatitis64 54 occasional (7.5%) Occasional (29-5%) HP:0001733
20 thrombocytopenia64 54 occasional (7.5%) Occasional (29-5%) HP:0001873
21 anemia64 54 occasional (7.5%) Occasional (29-5%) HP:0001903
22 abdominal pain64 54 occasional (7.5%) Occasional (29-5%) HP:0002027
23 restrictive ventilatory defect64 occasional (7.5%) HP:0002091
24 respiratory insufficiency64 occasional (7.5%) HP:0002093
25 abnormality of the pleura64 54 occasional (7.5%) Occasional (29-5%) HP:0002103
26 recurrent respiratory infections64 54 occasional (7.5%) Occasional (29-5%) HP:0002205
27 gastrointestinal hemorrhage64 54 occasional (7.5%) Occasional (29-5%) HP:0002239
28 elevated hepatic transaminases64 54 occasional (7.5%) Occasional (29-5%) HP:0002910
29 acute hepatic failure64 54 occasional (7.5%) Occasional (29-5%) HP:0006554
30 inflammatory abnormality of the eye64 occasional (7.5%) HP:0100533
31 abnormality of the preputium64 occasional (7.5%) HP:0100587
32 sepsis64 54 occasional (7.5%) Occasional (29-5%) HP:0100806
33 corneal erosion64 54 occasional (7.5%) Occasional (29-5%) HP:0200020
34 conjunctivitis54 Occasional (29-5%)
35 entropion54 Occasional (29-5%)
36 myocardial infarction54 Occasional (29-5%)
37 fever54 Very frequent (99-80%)
38 hypokalemic metabolic alkalosis54 Occasional (29-5%)
39 diarrhea54 Very frequent (99-80%)
40 dysphagia54 Frequent (79-30%)
41 esophageal stricture54 Occasional (29-5%)
42 restrictive lung disease54 Occasional (29-5%)
43 dyspnea54 Occasional (29-5%)
44 erythema54 Very frequent (99-80%)
45 fatigue54 Very frequent (99-80%)
46 macule54 Very frequent (99-80%)
47 cough54 Occasional (29-5%)
48 dyspareunia54 Occasional (29-5%)
49 dysuria54 Occasional (29-5%)

UMLS symptoms related to Hypersensitivity Syndrome, Carbamazepine-Induced:


mucosal toxicity, coma blister, infusion related reaction, muscle weakness, observation of narrowing of palpebral fissure, injection site hypersensitivity

MGI Mouse Phenotypes related to Hypersensitivity Syndrome, Carbamazepine-Induced according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107717.3CD4, CD8A, FAS, FASLG, HSPG2, IKZF1

Drugs & Therapeutics for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Drugs for Hypersensitivity Syndrome, Carbamazepine-Induced (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 88)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EphedrineapprovedPhase 4, Phase 1, Phase 2606299-42-39294
Synonyms:
( )-Pseudoephedrine
(+)-Ephedrin
(+)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(+-)-Ephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
--EPHEDRINE
1-EPHEDRINE
1-Sedrin
134910_ALDRICH
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50-98-6
50906-05-3
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC-20231
AC-20292
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AI3-02761
AKOS000268842
AR-1A0126
AR-1I7143
Acunaso
Acunaso (TN)
Afrinol
Ambap299-42-3
BIDD:GT0817
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
Benylin Decongestant
Besan
Biophedrin
C01575
C02765
C10H15NO
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
Cenafed
D00124
D08449
DB00852
DB01364
Decofed
DivK1c_000181
DivK1c_000451
DivK1c_000461
Drixoral N.D.
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eciphin
Efedrin
Efidac/24
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine l-form
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
Fedrin
Genaphed
HSDB 3072
HSDB 3177
I-Sedrin
I01-3584
I01-8925
I01-8928
 
IDI1_000181
IDI1_000451
IDI1_000461
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
KST-1A9168
Kratedyn
L(+)-psi-Ephedrine
L(-)-Ephedrine
L-(+)-Ephedrine
L-(-)-Ephedrine
L-Ephedrine
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
L000968
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Lexofedrin
Lopac-E-3250
Lopac0_000501
MLS000069657
Manadrin
Mandrin
Maxenal
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI-C55652
NCI60_002955
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Nasol
Neodurasina
Neodurasina (TN)
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
Robidrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
ST023802
STK367993
STOCK1N-42675
Sanedrine
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
Spectrum_000878
Spectrum_001020
Sudafed
Sudafed Decongestant
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
d-Ephedrine
d-Isoephedrine
d-Pseudoephedrine
d-psi-Ephedrine
l-Ephedrine
l-Pseudoephedrine
racephedrine
trans-Ephedrine
2
PseudoephedrineapprovedPhase 4, Phase 1, Phase 260690-82-47028
Synonyms:
( )-Pseudoephedrine
(+) threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC-20292
AC1L1NUA
Acunaso
Acunaso (TN)
Afrinol
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
C02765
C10H15NO
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
Cenafed
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-Ephedrine
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
DivK1c_000451
Drixoral N.D.
Drixoral Nasal Decongestant
EINECS 202-018-6
Efidac 24 Pseudoephedrine Hcl
Efidac/24
Eltor 120
Ephedrine
Genaphed
HSDB 3177
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
 
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L(+)-Psi-Ephedrine
L(+)-psi-Ephedrine
L-(+)-Pseudoephedrine
LS-125922
Lopac-E-3250
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
NINDS_000451
Neodurasina
Neodurasina (TN)
Novafed
PDSP1_001347
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
Pseudoephedrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine D-form
Pseudoephedrine Ephedrine
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
STOCK1N-42675
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
Spectrum_000878
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
alpha-(1-(Methylamino)ethyl)benzyl alcohol
d-Isoephedrine
d-Pseudoephedrine
d-psi-2-Methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
pseudoéphédrine
trans-Ephedrine
ψ-ephedrine
3
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 391579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
4
Pyrimethamineapproved, vet_approvedPhase 415258-14-04993
Synonyms:
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine
46706_FLUKA
46706_RIEDEL
4753 R.P.
4753 r.p
5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE
5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE
5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
58-14-0
AB00052084
AC-7879
AC1L1JDI
AI3-25005
AZT + Pyrimethamine combination
Aventis Brand of Pyrimethamine
BIDD:GT0149
BIDD:PXR0173
BPBio1_000147
BRD-K88429204-001-05-4
BRN 0219864
BSPBio_000133
BSPBio_003282
BW 50-63
BW 5063
C07391
C12H13ClN4
CAS-58-14-0
CCRIS 546
CD
CHEBI:8673
CHEMBL36
CID4993
CP6
CPD000058714
CRL-8131 & Pyrimethamine
CRL-8142 & Pyrimethamine
Chloridin
Chloridine
Chloridyn
D00488
D011739
DB00205
Darachlor
Daraclor
Darapram
Daraprim
Daraprim (TN)
Daraprime
Daraprin
Diaminopyritamin
Disulone
DivK1c_000652
EINECS 200-364-2
EXR-101
Erbaprelina
Ethylpyrimidine
Fansidar
Fansidar (Pyrimethamine/Sulfadoxine)
Glaxo Wellcome Brand of Pyrimethamine
GlaxoSmithKline Brand of Pyrimethamine
HMS1568G15
HMS1920N12
HMS2092E13
HMS502A14
IDI1_000652
KBio1_000652
KBio2_001386
KBio2_003954
 
KBio2_006522
KBio3_002502
KBioGR_001007
KBioSS_001386
Khloridin
L000713
LS-238
Lactoferrin B & Pyrimethamine
Lactoferrin H & Pyrimethamine
MCB-3837
MLS000028606
MLS001148621
MLS002454446
MLS002701881
Malacid
Malocid
Malocide
Maloprim
MolPort-001-783-655
NCGC00016256-01
NCGC00016256-02
NCGC00023188-03
NCGC00023188-04
NCGC00023188-05
NCGC00023188-06
NCGC00023188-07
NCI-C01683
NCI60_002604
NCIOpen2_008313
NINDS_000652
NSC 3061
NSC-3061
NSC3061
Oxaquin
Pirimecidan
Pirimetamin
Pirimetamina
Pirimetamina [INN-Spanish]
Pirimetamina [Spanish]
Prestwick0_000037
Prestwick1_000037
Prestwick2_000037
Prestwick3_000037
Prestwick_504
Primethamine
Pyremethamine
Pyrimethamin
Pyrimethamine (JAN/USP/INN)
Pyrimethamine (Pyr)
Pyrimethamine Hcl
Pyrimethamine [USAN:INN:BAN:JAN]
Pyrimethaminum
Pyrimethaminum [INN-Latin]
RP 4753
S2006_Selleck
SAM002554921
SMR000058714
SPBio_000672
SPBio_002054
SPECTRUM1500520
Spectrum2_000886
Spectrum3_001701
Spectrum4_000494
Spectrum5_001447
Spectrum_000906
TCMDC-123831
TCMDC-125860
Tindurin
Tindurine
Tinduring
UNII-Z3614QOX8W
WLN: T6N CNJ BZ DZ ER DG& F2
WR 2978
Wellcome Brand of Pyrimethamine
ZINC00057464
m alocid
nchembio.215-comp13
nchembio.87-comp22
pyrimethamine
5
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
6
SulfadoxineapprovedPhase 41282447-57-617134
Synonyms:
2447-57-6
4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
4-Sulfanilamido-5,6-dimethoxypyrimidine
4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide
46810_RIEDEL
5-25-13-00306 (Beilstein Handbook Reference)
6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine
AB00514044
AC-11921
AC1L29DT
AC1Q46GG
Ambap2447-57-6
BPBio1_001286
BRD-K55250441-001-03-1
BRN 0625453
BSPBio_001168
C07630
CAS-2447-57-6
CHEBI:9329
CHEMBL1539
CID17134
D00580
DB01299
EINECS 219-504-9
Fanasil
Fanzil
HMS1571K10
HMS2090P07
HMS2094C19
I09-0529
LS-31247
MLS002154150
MolPort-003-850-341
N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide
N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
 
N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
NCGC00016612-01
NCGC00016612-02
Orthosulfin
Prestwick0_001094
Prestwick1_001094
Prestwick2_001094
Prestwick3_001094
Ro 4-4393
Ro-4-4393
S2511_Selleck
S7821_SIGMA
SMR000857259
SPBio_003054
SULFADOXINE
Sanasil: Sulfadoxine: Sulformetoxin
Solfadossina
Solfadossina [DCIT]
Sulfadoxin
Sulfadoxina
Sulfadoxina [INN-Spanish]
Sulfadoxine
Sulfadoxine (JAN/USP/INN)
Sulfadoxine [USAN:INN:BAN:JAN]
Sulfadoxinum
Sulfadoxinum [INN-Latin]
Sulformethoxine
Sulformetoxine
Sulforthomidine
Sulphadoxine
Sulphormethoxine
Sulphormetoxin
Sulphorthodimethoxine
UNII-88463U4SM5
WR 4073
WR 4873
ZINC00002094
7
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 1, Phase 2427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
8Pharmaceutical SolutionsPhase 4, Phase 3, Phase 1, Phase 27793
9Respiratory System AgentsPhase 4, Phase 1, Phase 24818
10Vasoconstrictor AgentsPhase 4, Phase 1, Phase 22027
11TetrahydrozolinePhase 4, Phase 1, Phase 2593
12Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
13Ophthalmic SolutionsPhase 4, Phase 1, Phase 21092
14Autonomic AgentsPhase 4, Phase 1, Phase 29774
15Nasal DecongestantsPhase 4, Phase 1, Phase 2578
16Folic Acid AntagonistsPhase 42200
17Renal AgentsPhase 4732
18Fanasil, pyrimethamine drug combinationPhase 4120
19Antifungal AgentsPhase 4, Phase 33615
20Vitamin B ComplexPhase 4, Phase 1, Phase 24229
21Antiparasitic AgentsPhase 42127
22Dermatologic AgentsPhase 4, Phase 3, Phase 1, Phase 25674
23Calcineurin InhibitorsPhase 4, Phase 31597
24Antiprotozoal AgentsPhase 41986
25Anti-Infective AgentsPhase 4, Phase 321402
26Immunosuppressive AgentsPhase 4, Phase 312770
27Antirheumatic AgentsPhase 4, Phase 3, Phase 1, Phase 210627
28AntimalarialsPhase 41216
29Vitamin B9NutraceuticalPhase 4, Phase 1, Phase 24279
30FolateNutraceuticalPhase 4, Phase 1, Phase 24279
31Folinic AcidNutraceuticalPhase 43150
32
Etanerceptapproved, investigationalPhase 3397185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
33
Lamotrigineapproved, investigationalPhase 3, Phase 218384057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
34
Valproic Acidapproved, investigationalPhase 332299-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
35
Coal tarapprovedPhase 31918007-45-2
Synonyms:
 
Coal tars
Tar, coal
36
Gabapentinapproved, investigationalPhase 2, Phase 328960142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
37Excitatory Amino AcidsPhase 3, Phase 21297
38Sodium Channel BlockersPhase 3, Phase 21515
39Excitatory Amino Acid AntagonistsPhase 3, Phase 21282
40Neurotransmitter AgentsPhase 3, Phase 217734
41ImmunoglobulinsPhase 36045
42AntibodiesPhase 36045
43Diuretics, Potassium SparingPhase 3, Phase 21827
44Immunoglobulins, IntravenousPhase 3324
45gamma-GlobulinsPhase 3317
46calcium channel blockersPhase 3, Phase 21940
47Rho(D) Immune GlobulinPhase 3317
48AnticonvulsantsPhase 3, Phase 22620
49Calcium, DietaryPhase 3, Phase 25525
50Gastrointestinal AgentsPhase 3, Phase 1, Phase 28109

Interventional clinical trials:

(show all 32)
idNameStatusNCT IDPhase
1Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeCompletedNCT01488396Phase 4
2IPT of Malaria With SP in Different Zones of Drug Resistance in RwandaCompletedNCT00372632Phase 4
3G-CSF in the Treatment of Toxic Epidermal NecrolysisRecruitingNCT02739295Phase 4
4Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.CompletedNCT01696500Phase 3
5Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface TransplantationCompletedNCT00346450Phase 3
6Clinical Evaluation of BW430C in EpilepsyCompletedNCT00395694Phase 3
7Aloe Vera on Irradiated Breast TissueCompletedNCT01824134Phase 3
8Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisNot yet recruitingNCT02987257Phase 3
9Lamictal in the Treatment of Post-Herpetic NeuralgiaTerminatedNCT00295776Phase 2, Phase 3
10Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell DeficiencyUnknown statusNCT00845117Phase 1, Phase 2
11Utilization of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal HealingCompletedNCT02746848Phase 1, Phase 2
12Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter TrialRecruitingNCT02318485Phase 2
13Use of Cross-linked Donor Corneas as Carriers for the Boston KeratoprosthesisRecruitingNCT01582880Phase 1, Phase 2
14Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet TransplantationAvailableNCT02149732Phase 1, Phase 2
15Topical Infliximab in Autoimmune Eyes With KeratoprosthesisEnrolling by invitationNCT02126020Phase 1, Phase 2
16Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisNot yet recruitingNCT02319616Phase 1, Phase 2
17Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisTerminatedNCT02037347Phase 1, Phase 2
18Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)WithdrawnNCT01256489Phase 1, Phase 2
19Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)WithdrawnNCT00372723Phase 2
20Topical Infliximab for Sterile Corneal MeltNot yet recruitingNCT02987686Phase 1
21Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry EyeUnknown statusNCT01122303
22Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug ReactionsUnknown statusNCT01276314
23Stevens-Johnson Syndrome AntimicrobialCompletedNCT00844038
24Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.CompletedNCT01178242
25Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic TreatmentsCompletedNCT01086319
26Severe Cutaneous Adverse Reactions in ThailandRecruitingNCT02574988
27An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine AcetateRecruitingNCT02520557
28Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyRecruitingNCT02795143
29Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCTRecruitingNCT02261506
30Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeRecruitingNCT02847728
31Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis ImplantationActive, not recruitingNCT02945176
32Immune Responses to Antigens in Non-infectious Eye Inflammatory DiseasesEnrolling by invitationNCT00357071

Search NIH Clinical Center for Hypersensitivity Syndrome, Carbamazepine-Induced

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Hypersensitivity Syndrome, Carbamazepine-Induced:
Cultivated corneal epithelial stem cells for treatment of ocular surface damage
Embryonic/Adult Cultured Cells Related to Hypersensitivity Syndrome, Carbamazepine-Induced:
Limbal corneal epithelial stem cells, PMIDs: 23055668


Cochrane evidence based reviews: stevens-johnson syndrome

Genetic Tests for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Anatomical Context for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

MalaCards organs/tissues related to Hypersensitivity Syndrome, Carbamazepine-Induced:

36
Skin, Eye, Neutrophil, T cells, Salivary gland, Lung

Publications for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Variations for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Expression for genes affiliated with Hypersensitivity Syndrome, Carbamazepine-Induced

About this section
Search GEO for disease gene expression data for Hypersensitivity Syndrome, Carbamazepine-Induced.

Pathways for genes affiliated with Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Pathways related to Hypersensitivity Syndrome, Carbamazepine-Induced according to GeneCards Suite gene sharing:

(show all 12)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8FAS, FASLG, GZMB
2
Show member pathways
9.5CD8A, FASLG, GZMB, HLA-A
3
Show member pathways
9.5CD4, GZMB, TLR3
4
Show member pathways
9.4CD4, CD8A, HLA-A
59.4CD4, CD8A, IKZF1
6
Show member pathways
9.4FAS, FASLG, GZMB, HLA-A, HLA-B
7
Show member pathways
9.3FAS, FASLG, HLA-A, HLA-B, TLR3
89.2CD4, CD8A, HLA-A, HLA-B
99.2CD4, CD8A, GZMB, IKZF1
10
Show member pathways
9.0CD4, CD8A, FASLG, GZMB, HLA-A
11
Show member pathways
8.6CD4, CD8A, FAS, FASLG, GZMB, HLA-A
128.1CD4, CD8A, FAS, FASLG, GZMB, IKZF1

GO Terms for genes affiliated with Hypersensitivity Syndrome, Carbamazepine-Induced

About this section

Cellular components related to Hypersensitivity Syndrome, Carbamazepine-Induced according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class I protein complexGO:004261210.4HLA-A, HLA-B
2T cell receptor complexGO:00421019.6CD4, CD8A
3external side of plasma membraneGO:00098979.6CD4, CD8A, FAS, FASLG
4cell surfaceGO:00099868.2CD4, CD8A, FAS, FASLG, HLA-A, HLA-B

Biological processes related to Hypersensitivity Syndrome, Carbamazepine-Induced according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:000248010.7HLA-A, HLA-B
2activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayGO:009729610.6FAS, FASLG
3inflammatory cell apoptotic processGO:000692510.5FAS, FASLG
4necroptotic processGO:007026610.4FASLG, TLR3
5regulation of extrinsic apoptotic signaling pathway via death domain receptorsGO:190204110.3FAS, FASLG
6antigen processing and presentationGO:001988210.3CD8A, HLA-A, HLA-B
7apoptotic signaling pathwayGO:009719010.2FAS, FASLG, TLR3
8extrinsic apoptotic signaling pathwayGO:009719110.2FAS, FASLG, TLR3
9necroptotic signaling pathwayGO:009752710.1FAS, FASLG, TLR3
10positive regulation of calcium-mediated signalingGO:005085010.1CD4, CD8A
11response to growth factorGO:007084810.0FAS, FASLG

Sources for Hypersensitivity Syndrome, Carbamazepine-Induced

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet